Biotech Values

[mcbio]

Re: MNTA/Copaxone "obviousness" argument

Quote:
--------------------------------------------------------------------------------
…which of the four arguments do you see as holding the best chance for MNTA to succeed?
--------------------------------------------------------------------------------

Obviousness/double patenting, i.e. that the Orange Book patents are obvious extensions of older Copaxone patents.

I would assume you are fairly confident that MNTA will in fact succeed on this argument. Is the general consensus in the analyst community and elsewhere that MNTA will not? One would think so given MNTA's market cap, although perhaps too many people are just too focused on the nearer-term potential issue of TEVA receiving approval for its generic Lovenox to see the opportunity that lies beyond for MNTA with generic Copaxone (and of course everything else in the pipeline from M118, FOBs, etc.). I.e., if we can be reasonably confident that MNTA will succeed on the "obviousness" argument in the Copaxone patent litigation, I'm really not all that worried at all even if TEVA does receive approval for its generic Lovenox in the near-term. In fact, I'm inclined to view such an event, and any material drop in MNTA's stock, as a potential buying opportunity.